MALVERN, Pa. , July 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC ® .
"We're proud to provide high-quality, affordable choices to healthcare providers and their appropriate patients," said Scott Sims , Senior Vice President and General Manager, Endo Injectable Solutions & Generics. "The launch of tiopronin delayed-release tablets strengthens our generic product portfolio and underscores our reputation as a reliable supplier." The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients.
As a demonstration of its commitment to patients, Endo is offering copay assistance for those who meet eligibility requirements. To learn more about Endo's Patient Assistance Program, patients can call (833) 727-4357. THIOLA EC ® is a registered trademark of Mission Pharmacal Company.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Tiopronin delayed-release tablets are contradicted in patients with hypersensitivity to tiopronin or any other components of tiopronin delayed-release tablets. WARNINGS AND PRECAUTIONS Proteinuria Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased ris.
